ethyl 4-amino-1-isopropyl-pyrrole-2-carboxylate | 486437-78-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: ethyl 4-amino-1-isopropyl-pyrrole-2-carboxylate
• 英文别名: Ethyl 4-amino-1-isopropyl-1H-pyrrole-2-carboxylate；ethyl 4-amino-1-propan-2-ylpyrrole-2-carboxylate
• CAS: 486437-78-9
• 化学式: C₁₀H₁₆N₂O₂
• 分子量: 196.249
• InChiKey: JUQSUPUCPSMFQK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  57.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 4-amino-1-isopropyl-pyrrole-2-carboxylate 在 氢氧化钾 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 72.0h， 生成 4-tert-Butoxycarbonylamino-1-isopropyl-1H-pyrrole-2-carboxylic acid
  参考文献：
  名称：

  DNA binding ligands with in vivo efficacy in murine models of bacterial infection: optimization of internal aromatic amino acids

  摘要：

  DNA binding ligands with potent antimicrobial activity against Gram-positive bacteria were further optimized by variation of the internal aromatic amino acids. This modification led to compounds with improved in vivo efficacy in lethal murine models of peritonitis (methicillin-resistant S. aureus, MRSA) and lung infection (S. pneumoniae). (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.02.047
• 作为产物：
  描述：

  ethyl 1-isopropyl-4-nitro-pyrrole-2-carboxylate 在 palladium on activated charcoal 作用下， 以 乙醇 为溶剂， 生成 ethyl 4-amino-1-isopropyl-pyrrole-2-carboxylate
  参考文献：
  名称：

  Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions

  摘要：

  根据权利要求1中定义的Aa、Ra、X1至X4、Het和R5至R7，本发明的化合物公式1包括这些化合物的同分异构体和盐，尤其是具有生理活性的盐，它们是微囊体甘油三酯转移蛋白（MTP）的有效抑制剂，含有这些化合物的药物及其用途，以及这些化合物的制备方法。

  公开号：

  US20030073836A1

文献信息

• Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals
  申请人：Boehringer Ingelheim Pharma KG

  公开号：US20030162788A1

  公开（公告）日：2003-08-28

  The invention relates to the use of fibrates for lowering the liver toxicity of MTP inhibitors as well as pharmaceutical compositions containing an MTP inhibitor and a fibrate.

  本发明涉及使用纤维酸衍生物来降低MTP抑制剂对肝脏的毒性，以及包含MTP抑制剂和纤维酸衍生物的药物组合物。
• Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions
  申请人：Boehringer Ingelheim Pharma KG

  公开号：US20030073836A1

  公开（公告）日：2003-04-17

  A compound of formula 1 wherein: A a , R a , X 1 to X 4 , Het, and R 5 to R 7 are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, which are valuable inhibitors of the microsomal triglyceride-transfer protein (MTP), medicaments containing these compounds and their use, as well as the preparation thereof.

  根据权利要求1中定义的Aa、Ra、X1至X4、Het和R5至R7，本发明的化合物公式1包括这些化合物的同分异构体和盐，尤其是具有生理活性的盐，它们是微囊体甘油三酯转移蛋白（MTP）的有效抑制剂，含有这些化合物的药物及其用途，以及这些化合物的制备方法。
• [EN] PYRROLYL SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7-ONES AND DERIVATIVES THEREOF AS THERAPEUTIC AGENTS<br/>[FR] PYRIDO[2,3-D]PYRIMIDIN-7-ONES PYRROLYL-SUBSTITUEES ET DERIVES DE CES DERNIERES UTILISES COMME AGENTS THERAPEUTIQUES
  申请人：WARNER LAMBERT CO

  公开号：WO2005105801A1

  公开（公告）日：2005-11-10

  The present invention provides pyrimidines of Formula (I): wherein R2, R4, R5, R6, R8 and J have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases, including inflammatory diseases, cardiovascular diseases, and cancers. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (I).

  本发明提供了式（I）的嘧啶类化合物：其中R2、R4、R5、R6、R8和J具有规范中定义的任何值，并其药学上可接受的盐，可用作治疗疾病的药物，包括炎症性疾病、心血管疾病和癌症。还提供了包含一种或多种式（I）化合物的药物组合物。
• Pyrrolyl Substituted Pyrido[2,3-D]Pyrimidin-7-Ones and Derivatives Thereof as Therapeutic Agents
  申请人：Bruendl Michelle Marie

  公开号：US20080255162A1

  公开（公告）日：2008-10-16

  The present invention provides pyrimidines of Formula I: wherein R 2 , R 4 , R 5 , R 6 , R 8 and J have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases, including inflammatory diseases, cardiovascular diseases, and cancers. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.

  本发明提供了式I的嘧啶化合物：其中R2、R4、R5、R6、R8和J具有规范中定义的任何值，以及其药学上可接受的盐，可用作治疗疾病的药物，包括炎症性疾病、心血管疾病和癌症。还提供了包含一个或多个式I化合物的制药组合物。
• PYRROLYL SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7-ONES AND DERIVATIVES THEREOF AS THERAPEUTIC AGENTS
  申请人：Warner-Lambert Company LLC

  公开号：EP1749004B1

  公开（公告）日：2007-09-19